Nasdaq Grcl News Today

Gracell Biotechnologies Inc. (NASDAQ:GRCL – Get Free Report) has received an average recommendation of “Hold” from the eight brokerages that are presently covering the company, Marketbeat reports. Five investment analysts have rated the stock with a hold recommendation and three have assigned a buy recommendation to the company. The average 1-year target price among brokerages […]

Shares of Gracell Biotechnologies Inc. (NASDAQ:GRCL – Get Free Report) have earned an average recommendation of “Hold” from the eight ratings firms that are covering the stock, Marketbeat reports. Five analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. The average 1 year price objective […]

SAN DIEGO and SUZHOU, China and SHANGHAI, China, Feb. 20, 2024 (GLOBE NEWSWIRE) -- Gracell Biotechnologies Inc. (“Gracell” or the “Company”, NASDAQ:...

Gracell Biotechnologies Inc. (NASDAQ:GRCL – Get Free Report)’s share price hit a new 52-week high during mid-day trading on Tuesday . The company traded as high as $10.22 and last traded at $10.21, with a volume of 474243 shares traded. The stock had previously closed at $10.18. Wall Street Analysts Forecast Growth Several research firms […]

Several brokerages have updated their recommendations and price targets on shares of Gracell Biotechnologies (NASDAQ: GRCL) in the last few weeks: 12/27/2023 – Gracell Biotechnologies had its “neutral” rating reaffirmed by analysts at Piper Sandler. They now have a $10.00 price target on the stock. 12/27/2023 – Gracell Biotechnologies had its “equal weight” rating reaffirmed […]

Gracell Biotechnologies (NASDAQ:GRCL – Get Free Report) and Evolva (OTCMKTS:ELVAF – Get Free Report) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their valuation, analyst recommendations, earnings, dividends, profitability, risk and institutional ownership. Insider & Institutional Ownership 22.0% of Evolva shares are […]

Piper Sandler reissued their neutral rating on shares of Gracell Biotechnologies (NASDAQ:GRCL – Free Report) in a research report sent to investors on Wednesday morning, Benzinga reports. The firm currently has a $10.00 target price on the stock. A number of other research analysts also recently commented on the company. Citigroup lowered their target price […]

HC Wainwright lowered shares of Gracell Biotechnologies (NASDAQ:GRCL – Free Report) from a buy rating to a neutral rating in a report released on Tuesday morning, MarketBeat reports. The firm currently has $10.00 target price on the stock, down from their prior target price of $13.00. HC Wainwright also issued estimates for Gracell Biotechnologies’ FY2026 […]

HC Wainwright lowered shares of Gracell Biotechnologies (NASDAQ:GRCL – Free Report) from a buy rating to a neutral rating in a research note issued to investors on Tuesday, Marketbeat.com reports. HC Wainwright currently has $10.00 target price on the stock, down from their previous target price of $13.00. HC Wainwright also issued estimates for Gracell […]

Gracell Biotechnologies (NASDAQ:GRCL – Get Free Report)‘s stock had its “neutral” rating reiterated by analysts at Piper Sandler in a report issued on Wednesday, Benzinga reports. They currently have a $10.00 target price on the stock. Piper Sandler’s price objective points to a potential upside of 0.81% from the company’s previous close. A number of […]